Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
West, Diana C., Kocherginsky, Masha , Tonsing-Carter, Eva , Dolcen, Deniz Nesli , Hosfield, David J., Lastra, Ricardo R. , Sinnwell, Jason P. , Bowie, Kathleen R. , Skor, Maxwell N., Pierce, Charles F., Styke, Sarah C., Kim, Caroline R. , Wet, Larischa de, Wang, Liewei , Győrffy, Balázs , Conzen, Suzanne D. , Thompson, Kevin J. , Greene, Geoffrey L , Sinnwell, Jason P , Harkless, Ryan V. , Boughey, Judy C. , Goetz, Matthew P. , Kalari, Krishna R. , Fleming, Gini F. , Győrffy, Balázs

Mayo Clinic

Clinical Cancer Research | April 10, 2018 | Volume: 24 | Issue: 14 | Pages: 3433-3446

10.1158/1078-0432.ccr-17-2793 | PMID 29636357 Get It

Abstract Purpose: Although high glucocorticoid receptor (GR) expression in early-stage estrogen receptor (ER)-negative breast cancer is associated with shortened relapse-free survival (RFS), how associated GR transcriptional activity contributes to aggressive breast cancer behavior is not well understood. Using potent GR antagonists and primary tumor gene expression data, we sought to identify a tumor-relevant gene signature based on GR activity that would be more predictive than GR expression alone. Experimental Design: Global gene expression and GR ChIP-sequencing were performed to identify GR-regulated genes inhibited by two chemically distinct GR antagonists, mifepristone and CORT108297. Differentially expressed genes from MDA-MB-231 cells were cross-evaluated with significantly expressed genes in GR-high versus GR-low ER-negative primary breast cancers. The resulting subset of GR-targeted genes was analyzed in two independent ER-negative breast cancer cohorts to derive and then validate the GR activity signature (GRsig). Results: Gene expression pathway analysis of glucocorticoid-regulated genes (inhibited by GR antagonism) revealed cell survival and invasion functions. GR ChIP-seq analysis demonstrated that GR antagonists decreased GR chromatin association for a subset of genes. A GRsig that comprised n = 74 GR activation-associated genes (also reversed by GR antagonists) was derived from an adjuvant chemotherapy-treated Discovery cohort and found to predict probability of relapse in a separate Validation cohort (HR = 1.9; P = 0.012). Conclusions: The GRsig discovered herein identifies high-risk ER-negative/GR-positive breast cancers most likely to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve outcome for these high-risk patients. Clin Cancer Res; 24(14); 3433–46. ©2018 AACR.
Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus
Kamboj, Amrit K. , Wolfsen, Herbert C. , Trindade, Arvind J. , Ganguly, Eric K. , Otaki, Fouad , Chan, Daniel K. , Zakko, Liam , Visrodia, Kavel , Lutzke, Lori S., Wang, Kenneth K, Leggett, Cadman L. , Kahn, Allon , Trindade, Arvind J , Chan, Daniel, Lutzke, Lori, Leggett, Cadman L , Otaki, Fouad

Mayo Clinic

Journal of Gastroenterology and Hepatology | April 10, 2018 | Volume: 33 | Issue: 10 | Pages: 1761-1765

10.1111/jgh.14153 | PMID 29633412 Get It

AbstractBackground and AimVolumetric laser endomicroscopy (VLE) is used to identify Barrett's esophagus (BE) dysplasia. Selection of a dysplastic region of interest (ROI) can be challenging due to feature variability across a large amount of data. The degree of agreement among VLE users in selecting a ROI has not been studied.MethodsHigh‐definition videos that divided a VLE scan from 18 patients with biopsy‐proven BE dysplasia into 1‐cm segments were reviewed using a four‐quadrant grid superimposed for systematic interpretation. VLE scans were selected based on image quality and appropriate visualization of BE epithelium. Four experienced VLE users rated each quadrant as dysplastic or non‐dysplastic. For quadrants rated as dysplastic, reviewers selected a single timeframe with representative features. A high‐degree of agreement among reviewers was defined as ≥75% agreement on the quadrant diagnosis and ≥50% agreement on selected timeframe (±2 s).ResultsThirty‐one videos, each 32 s in length, comprising 124 quadrants were reviewed. There was high‐agreement among reviewers in 99 (80%) quadrants, of which 68 (69%) were rated as dysplastic. Compared with quadrants rated as non‐dysplastic, ROIs of quadrants rated as dysplastic contained a higher number of epithelial glands (12.7 vs 1.2, P < 0.001) with atypical architecture (54 vs 1, P < 0.001). A statistically significant difference was observed between the signal intensity profiles of quadrants rated as dysplastic and quadrants rated as non‐dysplastic (P = 0.004).ConclusionThis study highlights that experienced VLE users can identify ROIs with high‐degree of agreement. Selected ROIs contained VLE features associated with BE dysplasia.
Weight Changes After Thyroid Surgery for Patients with Benign Thyroid Nodules and Thyroid Cancer: Population-Based Study and Systematic Review and Meta-Analysis
Ospina, Naykky Singh , Castañeda-Guarderas, Ana, Hamidi, Oksana , Ponce, Oscar J. , Zhen, Wang, Brito, Juan P. , Singh Ospina, Naykky, Hamidi, Oksana , Prokop, Larry J. , Montori, Víctor M. , Singh Ospina, Naykky , Brito, Juan P , Ponce, Oscar Josue

Mayo Clinic

Thyroid | April 10, 2018 | Volume: 28 | Issue: 5 | Pages: 639-649

10.1089/thy.2017.0216 | PMID 29631475 Get It

Neuroregeneration: Spatial Differences in Cellular and Molecular Responses as a Function of the Material Used in Conduit‐Mediated Repair and Autograft Treatment of Peripheral Nerve Injuries (Adv. Funct. Mater. 12/2018)
Daly, William T. , Niemier, Ryan, Dillon, Simon T. , Mirsky, Rhona, Jessen, Kristján R. , Windebank, Anthony J. , Wang, Huan , Pandit, Abhay

Mayo Clinic

Advanced Functional Materials | April 6, 2018 | Volume: 28 | Issue: 12 | Pages: No page available

10.1002/adfm.201870080 Get It

Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy
Wang, Rong , Zhou, Tingyang, Zuo, Li , Liu, Wei

Mayo Clinic

Oncotarget | April 6, 2018 | Volume: 9 | Issue: 26 | Pages: 18637-18647

10.18632/oncotarget.24746 | PMID 29719632 Get It

Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Ye, Zhenqing, Li, Ying , Leong, Hon S. , Eckel‐Passow, Jeanette E. , Kocher, Jean‐Pierre , Wang, Liguo , Leong, Hon Sing, Eckel-Passow, Jeanette, Leong, Hon S , Wang, Liguo , Dong, Haidong , Ma, Tao , Huang, Haojie , Liang, Han

Mayo Clinic

Clinical Cancer Research | April 4, 2018 | Volume: 24 | Issue: 14 | Pages: 3299-3308

10.1158/1078-0432.ccr-17-3008 | PMID 29618619 Get It

Abstract Purpose: Homozygous deletions play important roles in carcinogenesis. The genome-wide screening for homozygously deleted genes in many different cancer types with a large number of patient specimens representing the tumor heterogeneity has not been done. Experimental Design: We performed integrative analyses of the copy-number profiles of 10,759 patients across 31 cancer types from The Cancer Genome Atlas project. Results: We found that the type-I interferon, α-, and β-defensin genes were homozygously deleted in 19 cancer types with high frequencies (7%–31%, median = 12%; interquartile range = 10%–16.5%). Patients with homozygous deletion of interferons exhibited significantly shortened overall or disease-free survival time in a number of cancer types, whereas patients with homozygous deletion of defensins did not significantly associate with worse overall or disease-free survival. Gene expression analyses suggested that homozygous deletion of interferon and defensin genes could activate genes involved in oncogenic and cell-cycle pathways but repress other genes involved in immune response pathways, suggesting their roles in promoting tumorigenesis and helping cancer cells evade immune surveillance. Further analysis of the whole exomes of 109 patients with melanoma demonstrated that the homozygous deletion of interferon (P = 0.0029, OR = 11.8) and defensin (P = 0.06, OR = 2.79) genes are significantly associated with resistance to anti-CTLA4 immunotherapy. Conclusions: Our analysis reveals that the homozygous deletion of interferon and defensin genes is prevalent in human cancers, and importantly this feature can be used as a novel prognostic biomarker for immunotherapy resistance. Clin Cancer Res; 24(14); 3299–308. ©2018 AACR.
Genetic overlap between endometriosis and endometrial cancer: evidence from cross‐disease genetic correlation and GWAS meta‐analyses
Painter, Jodie N. , O’Mara, Tracy A. , Morris, Andrew P. , Cheng, Timothy, Gorman, Maggie, Martin, Lynn , Hodson, Shirley, Henders, Anjali K. , McEvoy, Mark , Holliday, Elizabeth , Scott, Rodney J. , Webb, Penelope M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Rübner, Matthias, Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Lambrechts, Diether , Annibali, Daniela , Depreeuw, Jeroen, Goode, Ellen L. , Cunningham, Julie M. , Dowdy, Sean C. , Trovik, Jone , Høivik, Erling A. , Werner, Henrica M.J., Krakstad, Camilla , Ashton, Katie A. , Otton, Geoffrey, Proietto, Tony, Tham, Emma , Mints, Miriam, Healey, Catherine S., Shah, Mitul , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Zondervan, Krina T. , Nyholt, Dale R. , MacGregor, Stuart , Tomlinson, Ian , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Fasching, Peter A , Dörk, Thilo , Lambrechts, Diether , Goode, Ellen L , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , O'Mara, Tracy A , Lambrechts, Diether , Brenner, Hermann , Ekici, Arif B , Michailidou, Kyriaki , MacGregor, Stuart , Jones, Angela , Martin, Nicholas G. , Gordon, Scott D. , Attia, John , Hall, Per N , Czene, Kamila , Dürst, Matthias , Amant, Frédéric , Vanderstichele, Adriaan , Winham, Stacey J. , Mints, Miriam , Ahmed, Shahana , Pharoah, Paul D.P. , Dunning, Alison M. , Dennis, Joe , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Montgomery, Grant W. , Spurdle, Amanda B. , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Medicine | April 2, 2018 | Volume: 7 | Issue: 5 | Pages: 1978-1987

10.1002/cam4.1445 | PMID 29608257 Get It

AbstractEpidemiological, biological, and molecular data suggest links between endometriosis and endometrial cancer, with recent epidemiological studies providing evidence for an association between a previous diagnosis of endometriosis and risk of endometrial cancer. We used genetic data as an alternative approach to investigate shared biological etiology of these two diseases. Genetic correlation analysis of summary level statistics from genomewide association studies (GWAS) using LD Score regression revealed moderate but significant genetic correlation (rg = 0.23, P = 9.3 × 10−3), and SNP effect concordance analysis provided evidence for significant SNP pleiotropy (P = 6.0 × 10−3) and concordance in effect direction (P = 2.0 × 10−3) between the two diseases. Cross‐disease GWAS meta‐analysis highlighted 13 distinct loci associated at P ≤ 10−5 with both endometriosis and endometrial cancer, with one locus (SNP rs2475335) located within PTPRD associated at a genomewide significant level (P = 4.9 × 10−8, OR = 1.11, 95% CI = 1.07–1.15). PTPRD acts in the STAT3 pathway, which has been implicated in both endometriosis and endometrial cancer. This study demonstrates the value of cross‐disease genetic analysis to support epidemiological observations and to identify biological pathways of relevance to multiple diseases.
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma
Solanky, Dipesh , Krishnamoorthi, Rajesh , Crews, Nicholas R. , Johnson, Michele L., Wolfsen, Herbert C. , Fleischer, David E., Ramirez, Francisco C. , Katzka, David A. , Buttar, Navtej , Iyer, Prasad G. , Crews, Nicholas, Johnson, Michele, Wolfsen, Herbert, Fleischer, David, Katzka, David, Wang, Kenneth

Mayo Clinic

Journal of Clinical Gastroenterology | April 2, 2018 | Volume: 53 | Issue: 5 | Pages: 361-365

10.1097/mcg.0000000000001027 | PMID 29608452 Get It

Goals: To investigate factors predictive of progression from nondysplastic Barrett esophagus (NDBE) or low-grade dysplasia (LGD) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) using a large, prospective cohort of patients, wherein all esophageal biopsies undergo expert gastrointestinal pathologist review. Background: Efficacy and cost-effectiveness of endoscopic surveillance to detect incident EAC in the setting of Barrett esophagus (BE), particularly in NDBE patients, is questioned. Previous studies have reported factors predictive of progression to EAC to guide surveillance intervals, but their strength is limited by small sample size and absence of expert gastrointestinal pathologist involvement in esophageal biopsy review. Study: NDBE and LGD subjects were identified from a prospective registry in a tertiary care center. “Progressors” were BE subjects who developed HGD/EAC>12 months after the initial NDBE or LGD diagnosis. Cox proportional hazards model were used to identify predictors of progression. Results: In total, 318 with NDBE and 301 with BE-LGD (mean age, 62.6 y, 85% male) were included. The mean follow-up was 5.3 years. The 7 NDBE and 21 LGD subjects progressed to HGD/EAC. BE length [hazards ratio (HR), 1.16; 95% confidence interval (CI), 1.03-1.29], presence of nodularity (HR, 4.98; 95% CI, 1.80-11.7), and baseline LGD (HR, 2.57; 95% CI, 1.13-6.57) were significant predictors of progression on multivariate analysis. Conclusions: In this well-defined cohort of NDBE and BE-LGD subjects, BE length, presence of LGD, and nodularity were independent predictors of progression to HGD/EAC. These factors may aid in identifying high-risk patients who may benefit from closer endoscopic surveillance/therapy.
GMPR: A robust normalization method for zero-inflated count data with application to microbiome sequencing data
Chen, Li , Reeve, James , Zhang, L. , Huang, Shengbing, Wang, Xuefeng , Chen, Jun

Mayo Clinic

PeerJ | April 2, 2018 | Volume: 6 | Issue: No issue available | Pages: e4600

10.7717/peerj.4600 | PMID 29629248 Get It

Normalization is the first critical step in microbiome sequencing data analysis used to account for variable library sizes. Current RNA-Seq based normalization methods that have been adapted for microbiome data fail to consider the unique characteristics of microbiome data, which contain a vast number of zeros due to the physical absence or under-sampling of the microbes. Normalization methods that specifically address the zero-inflation remain largely undeveloped. Here we propose geometric mean of pairwise ratios—a simple but effective normalization method—for zero-inflated sequencing data such as microbiome data. Simulation studies and real datasets analyses demonstrate that the proposed method is more robust than competing methods, leading to more powerful detection of differentially abundant taxa and higher reproducibility of the relative abundances of taxa.
A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn’s Disease: Progress Made and Future Directions
Dozois, Eric J. , Lightner, Amy L. , Wang, Zhen , Zubair, Abba C.

Mayo Clinic

Diseases of the Colon & Rectum | March 25, 2018 | Volume: 61 | Issue: 5 | Pages: 629-640

10.1097/dcr.0000000000001093 | PMID 29578916 Get It

BACKGROUND: There has been a surge in clinical trials studying the safety and efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease. OBJECTIVE: The purpose of this work was to systematically review the literature to determine safety and efficacy of mesenchymal stem cells for the treatment of refractory perianal Crohn’s disease. DATA SOURCES: Sources included PubMed, Cochrane Library Central Register of Controlled Trials, and Embase. STUDY SELECTION: Studies that reported safety and/or efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease were included. Two independent assessors reviewed eligible articles. INTERVENTION: The study intervention was delivery of mesenchymal stem cells to treat perianal Crohn’s disease. MAIN OUTCOMES MEASURES: Safety and efficacy of mesenchymal stem cells used to treat perianal Crohn’s disease were measured. RESULTS: Eleven studies met the inclusion criteria and were included in the systematic review. Three trials with a comparison arm were included in the meta-analysis. There were no significant increases in adverse events (OR = 1.07 (95% CI, 0.61–1.89); p = 0.81) or serious adverse events (OR = 0.53 (95% CI, 0.28–0.98); p = 0.04) in patients treated with mesenchymal stem cells. Mesenchymal stem cells were associated with improved healing as compared with control subjects at primary end points of 6 to 24 weeks (OR = 3.06 (95% CI, 1.05–8.90); p = 0.04) and 24 to 52 weeks (OR = 2.37 (95% CI, 0.90–6.25); p = 0.08). LIMITATIONS: The study was limited by its multiple centers and heterogeneity in the study inclusion criteria, mesenchymal stem cell origin, dose and frequency of delivery, use of scaffolding, and definition and time point of fistula healing. CONCLUSIONS: Although there have been only 3 trials conducted with control arms, existing data demonstrate improved efficacy and no increase in adverse or serious adverse events with mesenchymal stem cells as compared with control subjects for the treatment of perianal Crohn’s disease.